Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Radius Health Inc. researches and develops drug therapies. The Company focuses on helping treat osteoporosis by building new bone in patients, and women"s health conditions including menopause and age-related muscle loss. Radius Health serves customers in the United States.
Website: radiuspharm.com



Growth: Good revenue growth rate 11.5%, there is slowdown compared to average historical growth rates 23.2%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -22.0%. On average the margin is improving steadily. Gross margin is high, +90.4%.

Cash Flow Generation: Dividend yield for the last twelve months 4.1%. Free cash flow yield -3.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 232.9% higher than minimum and 43.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.4x by EV / Sales multiple , the company can be 71.9% overvalued

Key Financials (Download financials)

Ticker: RDUS
Share price, USD:  (-1.6%)18.41
year average price 19.57  


year start price 10.08 2023-04-21

min close price 10.08 2023-04-21

max close price 32.47 2023-09-01

current price 18.41 2024-04-19
Common stocks: 47 600 499

Dividend Yield:  4.1%
Last revenue growth (y/y):  11.5%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  23.2%
Historical growth of EBITDA:  0.0%
EV / Sales: 5.1x
Margin (EBITDA LTM / Revenue): -22.0%
Fundamental value created in LTM:
Market Cap ($m): 876
Net Debt ($m): 268
EV (Enterprise Value): 1 144
Price to Book: 1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-28Zacks Investment Research

Analysts Estimate Radius Recycling (RDUS) to Report a Decline in Earnings: What to Look Out for

2024-01-04Seeking Alpha

Schnitzer Steel Industries, Inc. (RDUS) Q1 2024 Earnings Call Transcript

2023-10-18Seeking Alpha

Radius Recycling: Holding After The Rebrand
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q2 2022 q1
date 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-06-30 2022-03-31
symbol RDUS RDUS RDUS RDUS RDUS RDUS
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-08-09 2022-05-05
acceptedDate 2023-11-29 19:00:00 2023-08-30 20:00:00 2023-05-31 00:00:00 2023-02-28 00:00:00 2022-08-09 08:02:22 2022-05-05 12:19:50
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q2 Q1
revenue 673M 718M 810M 756M 58M 43M
costOfRevenue 633M 628M 714M 683M 6M 4M
grossProfit 39M 90M 96M 73M 53M 39M
grossProfitRatio 0.059 0.125 0.118 0.097 0.904 0.901
researchAndDevelopmentExpenses 0 0 0 0 26M 23M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 63M 69M 69M 64M 34M 30M
otherExpenses -170 000 -273 000 -1M -99 000 0 0
operatingExpenses 63M 69M 69M 64M 61M 53M
costAndExpenses 697M 697M 782M 747M 66M 57M
interestIncome 0 0 0 0 88 000 14 000
interestExpense 5M 5M 5M 5M 5M 5M
depreciationAndAmortization 23M 23M 23M 22M 390 000 387 000
ebitda -23M 21M 26M 9M -7M -13M
ebitdaratio -0.034 0.030 0.033 0.012 -0.128 -0.303
operatingIncome -23M -24M 28M 9M -8M -13M
operatingIncomeRatio -0.034 -0.033 0.034 0.011 -0.135 -0.312
totalOtherIncomeExpensesNet 468 000 -45M -1M -616 000 -5M -5M
incomeBeforeTax -28M -29M 21M 4M -13M -18M
incomeBeforeTaxRatio -0.042 -0.041 0.026 0.005 -0.218 -0.423
incomeTaxExpense -10M -3M 7M -513 000 5M 5M
netIncome -18M -26M 13M 4M -18M -23M
netIncomeRatio -0.027 -0.036 0.017 0.006 -0.302 -0.535
eps -0.640 -0.920 0.480 0.160 -0.370 -0.490
epsdiluted -0.640 -0.920 0.470 0.150 -0.370 -0.490
weightedAverageShsOut 28M 28M 28M 28M 48M 47M
weightedAverageShsOutDil 28M 28M 29M 29M 48M 47M
link Link Link
finalLink Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q2 2022 q1
date 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-06-30 2022-03-31
symbol RDUS RDUS RDUS RDUS RDUS RDUS
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-08-09 2022-05-05
acceptedDate 2023-11-29 19:00:00 2023-08-30 20:00:00 2023-05-31 00:00:00 2023-02-28 00:00:00 2022-08-09 08:02:22 2022-05-05 12:19:50
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q2 Q1
cashAndCashEquivalents 4M 6M 5M 11M 72M 72M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 4M 6M 5M 11M 72M 72M
netReceivables 191M 210M 297M 241M 32M 30M
inventory 281M 279M 299M 287M 12M 13M
otherCurrentAssets 59M 55M 58M 55M 29M 31M
totalCurrentAssets 535M 550M 659M 593M 146M 146M
propertyPlantEquipmentNet 814M 822M 816M 802M 2M 2M
goodwill 344M 343M 391M 386M 0 0
intangibleAssets 33M 33M 34M 36M 5M 5M
goodwillAndIntangibleAssets 344M 343M 391M 386M 5M 5M
longTermInvestments 10M 11M 10M 12M 0 0
taxAssets 22M 23M 23M 22M 0 0
otherNonCurrentAssets -33M -33M -33M -34M 2M 2M
totalNonCurrentAssets 1 157M 1 166M 1 207M 1 188M 8M 8M
otherAssets 0 0 0 0 0 0
totalAssets 1 693M 1 716M 1 866M 1 781M 154M 154M
accountPayables 201M 209M 210M 213M 14M 16M
shortTermDebt 26M 26M 27M 27M 418 000 508 000
taxPayables 346 000 358 000 1M 763 000 0 0
deferredRevenue -189M -196M -198M -213M 0 0
otherCurrentLiabilities 79M 89M 304M 294M 73M 64M
totalCurrentLiabilities 305M 324M 342M 321M 88M 80M
longTermDebt 374M 340M 442M 397M 340M 340M
deferredRevenueNonCurrent 5M -6M -7M -988 000 0 0
deferredTaxLiabilitiesNonCurrent 48M 59M 62M 56M 0 0
otherNonCurrentLiabilities 82M 82M 88M 80M 0 0
totalNonCurrentLiabilities 503M 480M 585M 531M 340M 340M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 115M 116M 119M 114M 829 000 981 000
totalLiabilities 808M 804M 927M 853M 428M 420M
preferredStock 0 0 0 0 0 0
commonStock 28M 28M 28M 27M 5000.000 5000.000
retainedEarnings 871M 894M 925M 917M -1 399M -1 386M
accumulatedOtherComprehensiveIncomeLoss -40M -40M -40M -41M 50 000 6000.000
othertotalStockholdersEquity 22M 26M 23M 21M 1 126M 1 120M
totalStockholdersEquity 881M 908M 936M 925M -273M -266M
totalEquity 884M 912M 936M 925M -273M -266M
totalLiabilitiesAndStockholdersEquity 1 693M 1 716M 1 866M 1 781M 154M 154M
minorityInterest 3M 3M 4M 3M 0 0
totalLiabilitiesAndTotalEquity 1 693M 1 716M 1 866M 1 781M 154M 154M
totalInvestments 10M 11M 10M 12M 0 0
totalDebt 399M 365M 469M 424M 340M 340M
netDebt 395M 359M 465M 412M 268M 269M
link Link Link
finalLink Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q2 2022 q1
date 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-06-30 2022-03-31
symbol RDUS RDUS RDUS RDUS RDUS RDUS
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-08-09 2022-05-05
acceptedDate 2023-11-29 19:00:00 2023-08-30 20:00:00 2023-05-31 00:00:00 2023-02-28 00:00:00 2022-08-09 08:02:22 2022-05-05 12:19:50
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q2 Q1
netIncome -18M -26M 14M 4M -13M -18M
depreciationAndAmortization 23M 23M 23M 22M 390 000 387 000
deferredIncomeTax -11M -3M 5M -596 000 0 0
stockBasedCompensation 1M 3M 3M 2M 5M 4M
changeInWorkingCapital 2M 93M -69M 60M 8M -27M
accountsReceivables 16M 83M -57M -31M 4M -7M
inventory 293 000 25M -11M 62M 805 000 -2M
accountsPayables 353 000 -5M -2M 31M -1M -2M
otherWorkingCapital -14M -9M 385 000 -2M 4M -16M
otherNonCashItems 996 000 88M 3M -438 000 413 000 415 000
netCashProvidedByOperatingActivities -1M 135M -21M 88M 1M -40M
investmentsInPropertyPlantAndEquipment -25M -28M -27M -27M -192 000 -157 000
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites -24M -27M 8M 807 000 0 0
netCashUsedForInvestingActivites -24M -27M -19M -26M -192 000 -157 000
debtRepayment -101M -225M -129M -195M 0 0
commonStockIssued 0 0 0 0 0 482 000
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid -6M -5M -5M -5M 0 0
otherFinancingActivites 130M 123M 168M 147M 0 0
netCashUsedProvidedByFinancingActivities 24M -107M 33M -54M 0 482 000
effectOfForexChangesOnCash 58 000 23 000 9000.000 -24 000 0 0
netChangeInCash -2M 2M -7M 8M 876 000 -40M
cashAtEndOfPeriod 4M 6M 5M 11M 73M 72M
cashAtBeginningOfPeriod 6M 5M 11M 4M 72M 112M
operatingCashFlow -1M 135M -21M 88M 1M -40M
capitalExpenditure -25M -28M -27M -27M -192 000 -157 000
freeCashFlow -26M 107M -48M 61M 876 000 -40M
link Link Link
finalLink Link Link

Earning call transcript

2024 q1
2024-01-04 ET (fiscal 2024 q1)
2023 q4
2023-10-25 ET (fiscal 2023 q4)
2023 q2
2023-04-05 ET (fiscal 2023 q2)
2023 q1
2023-01-05 ET (fiscal 2023 q1)
2022 q4
2022-10-24 ET (fiscal 2022 q4)
2022 q3
2022-06-29 ET (fiscal 2022 q3)
2022 q2
2022-04-06 ET (fiscal 2022 q2)
2022 q1
2022-05-06 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-04 12:00 ET
Radius Recycling Reports Second Quarter Fiscal 2024 Financial Results
2024-03-14 20:35 ET
Second Quarter Fiscal 2024 Preliminary Results and Announcement of Earnings Date
2024-03-04 13:30 ET
Radius Recycling Named One of the 2024 World’s Most Ethical Companies
2024-01-04 13:00 ET
Radius Recycling Reports First Quarter Fiscal 2024 Financial Results
2023-12-18 14:00 ET
Radius Recycling Announces First Quarter Fiscal 2024 Earnings Date and Webcast Details
2023-12-13 14:15 ET
Radius Recycling Publishes Fiscal Year 2023 Sustainability Report
2023-11-16 13:30 ET
Radius Recycling Executive Included on TIME100 Climate List of the 100 Most Influential Leaders Driving Business Climate Action
2023-10-25 12:00 ET
Radius Recycling Reports Fourth Quarter and Fiscal 2023 Financial Results
2023-09-29 12:30 ET
Radius Recycling Announces Fourth Quarter and Fiscal 2023 Earnings Date and Webcast Details
2022-08-15 13:00 ET
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
2022-08-11 10:42 ET
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
2022-07-11 12:00 ET
Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health
2022-07-07 22:30 ET
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
2022-07-07 12:00 ET
Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
2022-06-24 12:30 ET
Velan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital
2022-06-23 13:15 ET
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
2022-06-22 22:24 ET
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
2022-06-22 20:30 ET
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
2022-06-21 11:00 ET
Velan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to Stockholders
2022-06-16 13:00 ET
Rubric Capital Management Sends Letter to Radius Health Board of Directors
2022-06-13 11:00 ET
Velan-Repertoire Responds to Misleading Characterizations by the Radius Board
2022-06-08 12:00 ET
Radius Health Expands Non-US Market Footprint for TYMLOS
2022-06-07 11:00 ET
Velan-Repertoire Group Files Definitive Proxy Materials in Connection With Radius Health 2022 Annual Meeting
2022-06-06 14:54 ET
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-06-06 13:00 ET
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-06-06 11:30 ET
Radius Files Definitive Proxy and Mails Letter to Stockholders
2022-06-01 20:15 ET
Radius Health Update on Abaloparatide Transdermal System
2022-05-20 13:00 ET
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors
2022-05-20 07:57 ET
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
2022-05-19 21:00 ET
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
2022-05-05 11:30 ET
Radius Health, Inc. First Quarter 2022 Results
2022-04-25 12:30 ET
Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022
2022-04-05 12:00 ET
Radius Provides Agenda for Today’s R&D Webcast
2022-03-16 12:30 ET
Radius Health Announces Leadership Appointments
2022-03-08 13:30 ET
Radius Health Provides Business Update on Bone Health
2022-03-07 13:30 ET
Wells Fargo Equity Research to Host Fireside Chat with Radius CEO
2022-03-03 21:05 ET
Radius to Host Neuroscience R&D Webcast April 5, 2022
2022-03-01 13:00 ET
Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis
2022-02-24 12:30 ET
Radius Health, Inc. Fourth Quarter & Full Year 2021 Results
2022-02-15 17:00 ET
Radius Health to Release Fourth Quarter and Full Year 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, February 24, 2022
2022-01-13 14:00 ET
Radius Health Completes Business Adjustment
2021-12-23 13:30 ET
Radius Announces Update on TYMLOS® (abaloparatide) Label
2021-12-08 15:15 ET
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
2021-12-08 14:00 ET
Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis
2021-12-08 14:00 ET
Radius Health to Host Conference Call Today, Wednesday, December 8, 2021
2021-11-11 13:30 ET
Radius Health to Participate in the Stifel 2021 Virtual Healthcare Conference
2021-11-08 13:00 ET
Radius Health, Inc.: Third Quarter 2021 Results
2021-10-20 19:00 ET
Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021

SEC forms

Show financial reports only

SEC form 6
2022-08-15 11:38 ET
Radius Health published news for 2022 q2
SEC form 10
2022-08-09 08:02 ET
Radius Health reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Radius Health reported for 2022 q2
SEC form 6
2022-08-02 16:32 ET
Radius Health published news for 2022 q2
SEC form 6
2022-07-28 16:16 ET
Radius Health published news for 2022 q2
SEC form 6
2022-06-27 16:18 ET
Radius Health published news for 2022 q1
SEC form 6
2022-06-23 17:03 ET
Radius Health published news for 2022 q1
SEC form 6
2022-06-22 16:38 ET
Radius Health published news for 2022 q1
SEC form 6
2022-06-08 08:39 ET
Radius Health published news for 2022 q1
SEC form 6
2022-06-06 07:38 ET
Radius Health published news for 2022 q1
SEC form 6
2022-05-20 18:24 ET
Radius Health published news for 2022 q1
SEC form 10
2022-05-05 12:19 ET
Radius Health reported for 2022 q1
SEC form 6
2022-05-05 08:38 ET
Radius Health published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Radius Health reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Radius Health published news for 2022 q1
SEC form 6
2022-05-02 21:39 ET
Radius Health published news for 2022 q1
SEC form 6
2022-04-05 09:56 ET
Radius Health published news for 2022 q1
SEC form 6
2022-03-16 17:01 ET
Radius Health published news for 2021 q4
SEC form 10
2022-02-24 08:25 ET
Radius Health published news for 2021 q4
SEC form 6
2022-02-24 08:23 ET
Radius Health published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Radius Health published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Radius Health published news for 2021 q4
SEC form 6
2022-02-23 17:07 ET
Radius Health published news for 2021 q4
SEC form 6
2021-11-15 17:00 ET
Radius Health published news for 2021 q3
SEC form 10
2021-11-08 08:22 ET
Radius Health published news for 2021 q3
SEC form 6
2021-11-08 08:15 ET
Radius Health published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Radius Health published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Radius Health published news for 2021 q3
SEC form 6
2021-09-27 17:00 ET
Radius Health published news for 2021 q2
SEC form 6
2021-08-25 18:12 ET
Radius Health published news for 2021 q2
SEC form 10
2021-08-05 08:14 ET
Radius Health published news for 2021 q2
SEC form 6
2021-08-05 07:16 ET
Radius Health published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Radius Health published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Radius Health published news for 2021 q2
SEC form 6
2021-06-11 17:20 ET
Radius Health published news for 2021 q1
SEC form 6
2021-05-21 16:45 ET
Radius Health published news for 2021 q1
SEC form 10
2021-05-07 07:30 ET
Radius Health published news for 2021 q1
SEC form 6
2021-05-07 07:00 ET
Radius Health published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
Radius Health published news for 2021 q1
SEC form 8
2021-05-07 00:00 ET
Radius Health published news for 2021 q1
SEC form 6
2021-04-22 13:00 ET
Radius Health published news for 2021 q1
SEC form 6
2021-03-05 07:32 ET
Radius Health published news for 2020 q4
SEC form 10
2021-02-25 07:35 ET
Radius Health published news for 2020 q4
SEC form 6
2021-02-25 07:15 ET
Radius Health published news for 2020 q4
SEC form 6
2021-01-06 06:15 ET
Radius Health published news for 2020 q4
SEC form 6
2021-01-04 17:00 ET
Radius Health published news for 2020 q4
SEC form 6
2020-12-18 08:00 ET
Radius Health published news for 2020 q3
SEC form 10
2020-11-05 14:53 ET
Radius Health published news for 2020 q3
SEC form 6
2020-11-05 08:00 ET
Radius Health published news for 2020 q3